Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 6Glioblastoma 5Prostatic Neoplasms 3Esophageal Neoplasms 3Urinary Bladder Neoplasms 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Childhood Brain Neoplasm 2Triple Negative Breast Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Pancreatic carcinoma, familial 1Pancreatic Neoplasms 1Pancreatic Intraductal Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Osteonecrosis 1Osteomyelitis 1Neurodegenerative Diseases 1Neoplasms 1Malignant Solid Neoplasm 1Lung Carcinoma Metastatic in the Brain 1Liver Neoplasms 1Liver Cirrhosis 1Kidney Neoplasms 1

Interventions

prednylidene 1exifone 1deltacortene 1Prednisone 1Methylprednisolone 1Medrol Veriderm 1Magnetic Resonance Spectroscopy 1Gadolinium 1Ferrosoferric Oxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cranial Nerve Diseases × Ferrosoferric Oxide × Clear all
NCT03270059 2026-02-27

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

OHSU Knight Cancer Institute

Phase 2 Recruiting
150 enrolled
CNS

Brain Neoplasms, Cranial Nerve Diseases, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡